Can-Fite BioPharma Ltd. Sale of Stock, Consideration Received Per Transaction
Can-Fite BioPharma Ltd. (CANF) reported Sale of Stock, Consideration Received Per Transaction of $3.00 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-26.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedPerTransaction · last filed 2026-03-26
| Period end | Sale of Stock, Consideration Received Per Transaction 12 month |
|---|---|
| 2025-12-31 | $3.00M 20-F · filed 2026-03-26 |